$NTLA
Intellia Therapeutics, Inc.

2017 Q2 Form 10-Q Financial Statement

#000119312517154107 Filed on May 02, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q4
Revenue $5.917M $6.215M $5.630M
YoY Change 40.55% 249.16% 233.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.370M $5.730M $5.120M
YoY Change 70.78% 76.31% 82.21%
% of Gross Profit
Research & Development $15.57M $13.43M $11.33M
YoY Change 109.69% 157.05% 158.99%
% of Gross Profit
Depreciation & Amortization $710.0K $660.0K $400.0K
YoY Change 195.83% 252.94% 207.69%
% of Gross Profit
Operating Expenses $15.57M $13.43M $11.33M
YoY Change 109.69% 157.05% 158.99%
Operating Profit -$16.02M -$12.95M -$10.82M
YoY Change 130.59% 93.43% 97.09%
Interest Expense $420.0K $320.0K $260.0K
YoY Change 740.0% 3100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$15.59M -$12.63M -$10.56M
YoY Change 125.94% 88.82% 92.37%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$15.59M -$12.63M -$10.56M
YoY Change 125.99% 88.83% 101.39%
Net Earnings / Revenue -263.53% -203.23% -187.62%
Basic Earnings Per Share
Diluted Earnings Per Share -$446.4K -$363.8K -$305.3K
COMMON SHARES
Basic Shares Outstanding 36.03M shares 36.02M shares 36.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $241.0M $257.6M $273.1M
YoY Change -19.85% 301.25% 260.29%
Cash & Equivalents $241.0M $257.6M $273.1M
Short-Term Investments
Other Short-Term Assets $2.100M $1.100M $1.800M
YoY Change 75.0% 57.14% 125.0%
Inventory
Prepaid Expenses
Receivables $2.800M $2.443M $6.454M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $245.9M $261.1M $281.3M
YoY Change -18.82% 295.95% 262.39%
LONG-TERM ASSETS
Property, Plant & Equipment $12.60M $11.42M $10.63M
YoY Change 185.0% 170.06% 292.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.500M $6.767M $7.035M
YoY Change 97.03% 25.9% 289.75%
Total Long-Term Assets $19.10M $18.19M $17.66M
YoY Change 147.41% 89.37% 291.38%
TOTAL ASSETS
Total Short-Term Assets $245.9M $261.1M $281.3M
Total Long-Term Assets $19.10M $18.19M $17.66M
Total Assets $265.0M $279.3M $299.0M
YoY Change -14.69% 269.69% 263.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.300M $1.434M $4.652M
YoY Change 120.73% 18.91% 242.06%
Accrued Expenses $5.300M $3.559M $5.900M
YoY Change 23.6% 19.71% 111.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.40M $24.91M $30.73M
YoY Change 22.13% 127.28% 187.33%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $51.00M $378.0K $293.0K
YoY Change 13949.59% 8.31% -9.29%
Total Long-Term Liabilities $51.00M $378.0K $293.0K
YoY Change 13949.59% 8.31% -9.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.40M $24.91M $30.73M
Total Long-Term Liabilities $51.00M $378.0K $293.0K
Total Liabilities $77.40M $25.29M $31.02M
YoY Change 252.14% 123.61% 181.57%
SHAREHOLDERS EQUITY
Retained Earnings -$81.79M -$66.20M -$53.57M
YoY Change 130.24% 131.27% 144.21%
Common Stock $269.4M $266.1M $263.4M
YoY Change 3.96% 17842.28% 35737.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $187.6M $199.9M $209.8M
YoY Change
Total Liabilities & Shareholders Equity $265.0M $279.3M $299.0M
YoY Change -14.7% 269.69% 263.98%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$15.59M -$12.63M -$10.56M
YoY Change 125.99% 88.83% 101.39%
Depreciation, Depletion And Amortization $710.0K $660.0K $400.0K
YoY Change 195.83% 252.94% 207.69%
Cash From Operating Activities -$15.68M -$11.40M -$14.41M
YoY Change -123.21% 21.02% 162.48%
INVESTING ACTIVITIES
Capital Expenditures -$1.270M $4.162M -$3.410M
YoY Change 10.43% 312.9% 305.95%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$1.270M -$4.160M -$3.410M
YoY Change 10.43% 311.88% 305.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 440.0K 50.00K 260.0K
YoY Change -99.74% -104.17% -157.78%
NET CHANGE
Cash From Operating Activities -15.68M -11.40M -14.41M
Cash From Investing Activities -1.270M -4.160M -3.410M
Cash From Financing Activities 440.0K 50.00K 260.0K
Net Change In Cash -16.51M -15.51M -17.56M
YoY Change -106.98% 33.36% 159.0%
FREE CASH FLOW
Cash From Operating Activities -$15.68M -$11.40M -$14.41M
Capital Expenditures -$1.270M $4.162M -$3.410M
Free Cash Flow -$14.41M -$15.56M -$11.00M
YoY Change -120.98% 49.23% 136.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36028677 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64192000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1532000
CY2017Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
255735000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
255735000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36025676 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36025676 shares
CY2017Q1 us-gaap Assets
Assets
279263000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
261078000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
2700000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
266080000
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
257551000
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2443000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
4000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
54092000
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1434000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19917000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2027000
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3559000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
279263000
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
378000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
24910000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6767000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17929000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11418000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.12
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
199883000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
25000000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.99
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
780588 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1174938 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.82
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66201000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1084000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5440000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4373222 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75816000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2703000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
270448000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
270448000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36018540 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36018540 shares
CY2016Q4 us-gaap Assets
Assets
298969000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
281306000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
263403000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
273064000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6454000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
58109000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4652000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
20178000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3197000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5900000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
298969000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
293000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
30730000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7035000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10628000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
209837000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.35
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1361855 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.81
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53570000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1788000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3040214 shares
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5548000 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001652130
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-15513000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
378000
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5732000
CY2017Q1 us-gaap Depreciation
Depreciation
660000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
19163000
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
7136 shares
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1893000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-12631000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4162000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-4011000
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
6215000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-954000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-704000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-268000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12948000
CY2017Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
85000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
47000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4278000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
317000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11398000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4162000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M6D
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.71
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
186917 shares
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.03
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.73
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.56
CY2017Q1 dei Trading Symbol
TradingSymbol
NTLA
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13431000
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
47000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.926 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1343428 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.38
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.019 pure
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3284 shares
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2630000
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34723000 shares
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4392000 shares
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11624000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.89
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
918000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3246000
CY2016Q1 us-gaap Depreciation
Depreciation
187000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
8471000
CY2016Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
200000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-134000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-6689000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1008000
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1777000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-87000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-65000
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2823000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6694000
CY2016Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
26000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1195000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-778000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-9421000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1008000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5225000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.877 pure
CY2016Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
895000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.98
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.013 pure
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
812000
CY2016Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
676000 shares
CY2016Q1 ntla Initial Public Offering Costs Incurred But Not Yet Paid
InitialPublicOfferingCostsIncurredButNotYetPaid
454000
CY2016Q1 ntla Payments Of Temporary Equity Issuance Costs
PaymentsOfTemporaryEquityIssuanceCosts
100000
CY2016Q1 ntla In Process Research And Development Acquired But Not Yet Paid
InProcessResearchAndDevelopmentAcquiredButNotYetPaid
400000

Files In Submission

Name View Source Status
0001193125-17-154107-index-headers.html Edgar Link pending
0001193125-17-154107-index.html Edgar Link pending
0001193125-17-154107.txt Edgar Link pending
0001193125-17-154107-xbrl.zip Edgar Link pending
d378762d10q.htm Edgar Link pending
d378762dex311.htm Edgar Link pending
d378762dex312.htm Edgar Link pending
d378762dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g378762g57k66.jpg Edgar Link pending
ntla-20170331.xml Edgar Link completed
ntla-20170331.xsd Edgar Link pending
ntla-20170331_cal.xml Edgar Link unprocessable
ntla-20170331_def.xml Edgar Link unprocessable
ntla-20170331_lab.xml Edgar Link unprocessable
ntla-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending